公开(公告)号：WO2007004526A2

公开(公告)日：2007-01-11

申请号：PCT/JP2006/313038

申请日：2006-06-23

Applicant: ONCOTHERAPY SCIENCE, INC. ,  THE UNIVERSITY OF TOKYO ,  NAKAMURA, Yusuke ,  FURUKAWA, Yoichi ,  HAMAMOTO, Ryuji ,  NAKATSURU, Shuichi

Inventor： NAKAMURA, Yusuke ,  FURUKAWA, Yoichi ,  HAMAMOTO, Ryuji ,  NAKATSURU, Shuichi

IPC: C12Q1/48 ,  G01N33/68 ,  A61P35/00 ,  A61K38/00

CPC classification number: G01N33/5011 ,  C12Q1/48 ,  C12Y201/01043 ,  G01N33/57407 ,  G01N2333/4736 ,  G01N2333/91011 ,  G01N2500/02

Abstract: The present invention features a method for determining the methyltransferase activity of a polypeptide and screening for modulators of methyltransferase activity, more particularly for modulators of the methylation of retinoblastoma by SMYD3. The invention further provides a method or pharmaceutical composition for prevention or treating of colorectal cancer, hepatocellular carcinoma, bladder cancer and/or breast cancer using a modulator so identified.

Abstract translation: 本发明的特征在于确定多肽的甲基转移酶活性并筛选甲基转移酶活性的调节剂的方法，更特别是用于通过SMYD3进行视网膜母细胞瘤甲基化的调节剂。 本发明还提供了使用所鉴定的调节剂预防或治疗结肠直肠癌，肝细胞癌，膀胱癌和/或乳腺癌的方法或药物组合物。

公开(公告)号：WO2005118796A2

公开(公告)日：2005-12-15

申请号：PCT/US2005/018840

申请日：2005-05-27

Applicant: THE UNIVERSITY OF NORTH CAROLINA AT CHAPEL HILL ,  ZHANG, Yi ,  CAO, Ru

Inventor： ZHANG, Yi ,  CAO, Ru

IPC: C12N9/00

CPC classification number: C12N9/1007 ,  C07K14/82 ,  C07K2319/20 ,  C12N2799/026 ,  C12Y201/01043 ,  G01N2333/91011

Abstract: The present invention provides a reconstituted complex including EED, EZH2 and SUZ12 wherein the reconstituted complex has histone methyltransferase (HMTase) activity for lysine 27 of histone H3 (H3-K27). The reconstituted complex may further include RbAp48, AEBP2 or both. Also disclosed are methods of producing the reconstituted complex, methods of identifying compounds that inhibit the HTMase activity of the reconstituted complex and methods of identifying candidate compounds for treating cancer. Reagents and kits including the reconstituted complex are further provided.

Abstract translation: 本发明提供了包含EED，EZH2和SUZ12的复原复合物，其中重构的复合物对组蛋白H3（H3-K27）的赖氨酸27具有组蛋白甲基转移酶（HMTase）活性。 重构的复合物还可以包括RbAp48，AEBP2或两者。 还公开了生产重建复合物的方法，鉴定抑制重构复合物的HTMase活性的化合物的方法和鉴定用于治疗癌症的候选化合物的方法。 还提供了试剂和试剂盒，包括重构的复合物。

公开(公告)号：WO2013067302A1

公开(公告)日：2013-05-10

申请号：PCT/US2012/063243

申请日：2012-11-02

Applicant: GLAXOSMITHKLINE INTELLECTUAL PROPERTY (NO. 2) LIMITED ,  BASSIL, Anna, K. ,  BEINKE, Soren ,  PRINJHA, Rabinder, Kumar

Inventor： BASSIL, Anna, K. ,  BEINKE, Soren ,  PRINJHA, Rabinder, Kumar

IPC: C12N9/10 ,  A61P37/00

CPC classification number: A61K31/444 ,  A61K31/4545 ,  A61K31/496 ,  A61K31/506 ,  A61K31/513 ,  A61K31/517 ,  A61K31/5377 ,  C12N9/1007 ,  C12Y201/01043 ,  Y02A50/401 ,  Y02A50/414

Abstract: The present invention relates to a method of treating T cell mediated inflammatory immune diseases or T cell mediated hypersensitivity diseases, which comprises administering to a human in need thereof an effective amount of a compound which inhibits EZH2 and/or EZH1, or a pharmaceutically acceptable salt thereof.

公开(公告)号：WO2012164936A1

公开(公告)日：2012-12-06

申请号：PCT/JP2012/003569

申请日：2012-05-31

Applicant: ONCOTHERAPY SCIENCE, INC. ,  HAMAMOTO, Ryuji ,  NAKAMURA, Yusuke ,  TSUNODA, Takuya

Inventor： HAMAMOTO, Ryuji ,  NAKAMURA, Yusuke ,  TSUNODA, Takuya

IPC: C12N15/09 ,  A61K31/713 ,  A61K48/00 ,  A61P35/00 ,  C12N15/113 ,  C12Q1/02 ,  C12Q1/68 ,  G01N33/15 ,  G01N33/50 ,  G01N33/574

CPC classification number: C12Q1/6886 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/48 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Y201/01043 ,  G01N33/5011 ,  G01N33/57407 ,  G01N33/57411 ,  G01N33/57423 ,  G01N33/57434 ,  G01N2500/04

Abstract: Objective methods for detecting or diagnosing cancer, or determining a predisposition for developing cancer, particularly lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor, are described herein. In one embodiment, the diagnostic method involves determining an expression level of the SUV39H2 gene. The present invention further provides methods of screening for candidate substances useful in the treatment and/or prevention of an SUV39H2-associated cancer, such as lung cancer, cervical cancer, bladder cancer, esophageal cancer, osteosarcoma, prostate cancer and soft tissue tumor. The present invention further provides methods of inhibiting the cell growth and thereby treating or alleviating symptoms of an SUV39H2 associated cancer. The present invention also features double-stranded molecules against the SUV39H2 gene and vectors encoding thereof as well as compositions containing such components and their utility in connection with the treatment and prevention of an SUV39H2-associated cancer.

Abstract translation: 本文描述了用于检测或诊断癌症或确定发展癌症，特别是肺癌，子宫颈癌，膀胱癌，食管癌，骨肉瘤，前列腺癌和软组织肿瘤的倾向的客观方法。 在一个实施方案中，诊断方法包括确定SUV39H2基因的表达水平。 本发明还提供了筛选用于治疗和/或预防SUV39H2相关癌症（例如肺癌，子宫颈癌，膀胱癌，食管癌，骨肉瘤，前列腺癌和软组织肿瘤）的候选物质的方法。 本发明还提供了抑制细胞生长，从而治疗或减轻SUV39H2相关癌症症状的方法。 本发明还具有针对SUV39H2基因的双链分子及其编码载体以及含有这些组分的组合物及其与治疗和预防SUV39H2相关癌症有关的用途。

公开(公告)号：WO2011111072A9

公开(公告)日：2011-11-03

申请号：PCT/IN2011000161

申请日：2011-03-10

Applicant: TRANSGENE BIOTEK LTD ,  KOLLIPARA KOTESWARA RAO

Inventor： KOLLIPARA KOTESWARA RAO

IPC: C12N15/63

CPC classification number: C12N15/1137 ,  C12N15/111 ,  C12N2310/531 ,  C12N2330/51 ,  C12N2799/022 ,  C12Y201/01043

公开(公告)号：WO2009124137A3

公开(公告)日：2010-01-07

申请号：PCT/US2009039187

申请日：2009-04-01

Applicant: SINAI SCHOOL MEDICINE ,  ZHOU MING-MING ,  MUJTABA SHIRAZ

Inventor： ZHOU MING-MING ,  MUJTABA SHIRAZ

IPC: A61K38/00

CPC classification number: C12N9/1007 ,  A61K38/00 ,  A61K48/00 ,  C07K14/005 ,  C07K2319/09 ,  C12N2710/00022 ,  C12N2710/10343 ,  C12N2740/15043 ,  C12Y201/01043

Abstract: The present invention relates to methods of suppressing the transcriptional expression of one or more genes by methylating the chromatin histone proteins of the one or more genes. Specifically, a viral SET domain histone lysine mehtyltransferase (vSET or vSET-like protein) methylates lysine 27 of a gene's histone protein 3 (H3- K27) thereby suppressing the transcription of the gene.

Abstract translation: 本发明涉及通过甲基化一种或多种基因的染色质组蛋白蛋白来抑制一种或多种基因的转录表达的方法。 具体地，病毒SET结构域组蛋白赖氨酸甲酰转移酶（vSET或vSET样蛋白）使基因的组蛋白3（H3-K27）的赖氨酸27甲基化，从而抑制基因的转录。

公开(公告)号：WO2004076623A3

公开(公告)日：2004-12-23

申请号：PCT/JP2004002446

申请日：2004-02-27

Applicant: ONCOTHERAPY SCIENCE INC ,  JAPAN AS REPRESENTED BY THE PR ,  NAKAMURA YUSUKE ,  FURUKAWA YOICHI

Inventor： NAKAMURA YUSUKE ,  FURUKAWA YOICHI

IPC: A61K48/00 ,  C12N20060101 ,  C12N15/113 ,  C12N15/12 ,  C12N15/11

CPC classification number: C12N15/1135 ,  C12N2310/14 ,  C12N2310/531 ,  C12Y201/01043

Abstract: The invention features a method for inhibiting growth of a cancer cell by contacting the cell with a composition of a ZNFN3A1 siRNA. Methods of treating cancer are also within the invention. The invention also features products, including nucleic acid sequences and vectors as well as to compositions comprising them, useful in the provided methods. The invention also provides a method for inhibiting of tumer cell, for example liver or colon cancer cell, particularly HCC or colorectal adenocarcinoma.

Abstract translation: 本发明的特征在于通过使细胞与ZNFN3A1 siRNA的组合物接触来抑制癌细胞生长的方法。 治疗癌症的方法也在本发明的范围内。 本发明还包括可用于所提供的方法的产品，包括核酸序列和载体以及包含它们的组合物。 本发明还提供抑制肿瘤细胞的方法，例如肝脏或结肠癌细胞，特别是HCC或结肠直肠腺癌。

公开(公告)号：EP2638163B1

公开(公告)日：2017-05-17

申请号：EP11840099

申请日：2011-11-12

Applicant: MASSACHUSETTS GEN HOSPITAL

Inventor： LEE JEANNIE T ,  ZHAO JING ,  SARMA KAVITHA ,  BOROWSKY MARK ,  OHSUMI TOSHIRO KENDRICK

IPC: C12N15/113

CPC classification number: C12N15/1137 ,  A61K9/1271 ,  A61K31/713 ,  C12N15/113 ,  C12N15/1135 ,  C12N15/1136 ,  C12N2310/113 ,  C12N2310/14 ,  C12N2310/141 ,  C12N2310/314 ,  C12N2310/315 ,  C12N2310/3181 ,  C12N2310/321 ,  C12N2310/3231 ,  C12N2310/3233 ,  C12N2310/346 ,  C12N2320/30 ,  C12N2320/32 ,  C12N2330/31 ,  C12Q1/6876 ,  C12Q1/6881 ,  C12Q1/6886 ,  C12Q2600/136 ,  C12Q2600/158 ,  C12Q2600/178 ,  C12Y201/01043

Abstract: This invention relates to long non-coding RNAs (IncRNAs), libraries of those ncRNAs that bind chromatin modifiers, such as Polycomb Repressive Complex 2, inhibitory nucleic acids and methods and compositions for targeting IncRNAs. d

Abstract translation: 本发明涉及长非编码RNA（lncRNA），结合染色质修饰剂的那些ncRNA的文库，例如多梳抑制复合物2，抑制性核酸以及用于靶向lncRNA的方法和组合物。

公开(公告)号：EP2914298A4

公开(公告)日：2016-04-20

申请号：EP13850316

申请日：2013-11-04

Applicant: UNIV DUKE

Inventor： DZAU VICTOR J ,  MIROTSOU MARIA

IPC: A61K48/00 ,  A61K31/437 ,  A61K31/551 ,  A61K35/34 ,  A61K45/06 ,  A61P9/00 ,  C07D401/14 ,  C07D487/04 ,  C12N15/113

CPC classification number: A61K31/551 ,  A61K31/437 ,  A61K35/34 ,  A61K45/06 ,  C07D401/14 ,  C07D487/04 ,  C12N15/1137 ,  C12N2310/141 ,  C12N2320/30 ,  C12Y201/01043 ,  C12Y201/01125 ,  C12Y207/10002 ,  C12Y207/11001

Abstract: A method for promoting the reprogramming of a non-cardiomyocytic cell or tissue into cardiomyocytic cell or tissue comprising is carried out by contacting a non-cardiomyocytic cell or tissue with a modulator of histone methyltransferase activity or expression.

Abstract translation: 通过使非心肌细胞或组织与组蛋白甲基转移酶活性或表达的调节剂接触，来促进非心肌细胞或组织重编程成心肌细胞或组织的方法。

公开(公告)号：EP2908843A1

公开(公告)日：2015-08-26

申请号：EP13855314.4

申请日：2013-11-19

Applicant: Agency for Science, Technology and Research

Inventor： YU, Qiang ,  WEE, Zhen Ning

IPC: A61K38/21 ,  C07K14/555 ,  C07K14/715 ,  A61K31/52 ,  A61P35/00

CPC classification number: A61K38/217 ,  A61K31/437 ,  A61K31/706 ,  A61K31/713 ,  C07K16/40 ,  C07K2317/76 ,  C12N15/1137 ,  C12N2310/14 ,  C12Q1/6886 ,  C12Y201/01043 ,  G01N33/57492 ,  G01N33/57496 ,  G01N2800/52 ,  A61K2300/00

Abstract: The present invention relates to a pharmaceutical composition comprising a histone-lysine N-methyltransferase EZH2 (enhancer of zeste homolog 2) inhibitor and an enhancer of interferon-gamma receptor activity. The invention also relates to method of treating a patient having cancer, comprising administration of the pharmaceutical composition.

Abstract translation: 本发明涉及包含组蛋白 - 赖氨酸N-甲基转移酶EZH2（zeste同源物2的增强剂）抑制剂和干扰素-γ受体活性增强剂的药物组合物。 本发明还涉及治疗患有癌症的患者的方法，其包括施用所述药物组合物。